US2023218776A1PendingUtilityA1
Anti-ntb-a antibodies and related compositions and methods
Est. expiryJun 30, 2035(~8.9 yrs left)· nominal 20-yr term from priority
A61K 47/68035A61K 47/68031A61K 47/6811C07K 16/2803A61K 47/6851A61P 35/00A61K 47/65C07K 2317/24C07K 2317/33C07K 2317/567C07K 2317/73C07K 2317/732C07K 2317/92A61K 2039/572A61K 2039/505A61K 2121/00A61K 47/6803
70
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Disclosed are antibodies, including antibody drug conjugates, that specifically bind to NTB-A. Also disclosed are methods for using the anti-NTB-A antibodies to detect or modulate activity of (e.g., inhibit proliferation of) an NTB-A-expressing cell, as well as for diagnoses or treatment of diseases or disorders (e.g., cancer) associated with NTB-A-expressing cells, such as multiple myeloma, non-Hodgkin lymphoma and acute myeloid leukemia.
Claims
exact text as granted — not AI-modified1 . An antibody that specifically binds to the human NTB-A protein wherein the antibody comprises the three heavy chain complementarity determining regions of SEQ ID NO:3 and the 3 light chain CDRs of SEQ ID NO:13 wherein the CDRs are as defined by Kabat or IMGT.
2 - 52 . (canceled)Join the waitlist — get patent alerts
Track US2023218776A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.